MX2015011907A - Moduladores del canal de sodio para el tratamiento del dolor. - Google Patents

Moduladores del canal de sodio para el tratamiento del dolor.

Info

Publication number
MX2015011907A
MX2015011907A MX2015011907A MX2015011907A MX2015011907A MX 2015011907 A MX2015011907 A MX 2015011907A MX 2015011907 A MX2015011907 A MX 2015011907A MX 2015011907 A MX2015011907 A MX 2015011907A MX 2015011907 A MX2015011907 A MX 2015011907A
Authority
MX
Mexico
Prior art keywords
pain
treatment
sodium channel
channel modulators
compounds
Prior art date
Application number
MX2015011907A
Other languages
English (en)
Other versions
MX363680B (es
Inventor
Olga Babich
Robert Z Luo
Yanlin Wang-Fischer
David J Palling
Srinivasan P Venkatachalan
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of MX2015011907A publication Critical patent/MX2015011907A/es
Publication of MX363680B publication Critical patent/MX363680B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente compuestos que modulan el canal de sodio, en particular, compuestos que modulan el NaVl.7 de la Fórmula I. En particular, se proporcionan en la presente procesos para la preparación de compuestos intermediarios utilizados en la preparación de, composiciones farmacéuticas que los comprenden, y métodos terapéuticos que comprenden la administración de tales compuestos. En particular, se proporcionan en la presente compuestos para el tratamiento del dolor.
MX2015011907A 2013-03-15 2014-03-13 Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio. MX363680B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787618P 2013-03-15 2013-03-15
PCT/US2014/025809 WO2014151472A1 (en) 2013-03-15 2014-03-13 Sodium channel modulators for the treatment of pain

Publications (2)

Publication Number Publication Date
MX2015011907A true MX2015011907A (es) 2016-05-16
MX363680B MX363680B (es) 2019-03-29

Family

ID=51580969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011907A MX363680B (es) 2013-03-15 2014-03-13 Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio.

Country Status (16)

Country Link
US (1) US10179781B2 (es)
EP (1) EP2968234B1 (es)
JP (1) JP6449845B2 (es)
KR (1) KR20150131254A (es)
CN (1) CN105188694B (es)
AU (1) AU2014234105B2 (es)
BR (1) BR112015022096A8 (es)
CA (1) CA2900604A1 (es)
ES (1) ES2687481T3 (es)
HK (1) HK1219060A1 (es)
IL (1) IL242564A0 (es)
MX (1) MX363680B (es)
MY (1) MY188139A (es)
PH (1) PH12015501740A1 (es)
RU (1) RU2669367C2 (es)
WO (1) WO2014151472A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
AR091112A1 (es) 2012-05-22 2015-01-14 Genentech Inc Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7
EP2870138B1 (en) 2012-07-06 2018-08-22 Genentech, Inc. N-substituted benzamides and methods of use thereof
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
RU2669367C2 (ru) 2013-03-15 2018-10-11 Хромоселл Корпорейшн Модуляторы натриевого канала для лечения боли
MY181928A (en) * 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes
EP3074377B1 (en) 2013-11-27 2018-10-17 Genentech, Inc. Substituted benzamides and methods of use thereof
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
US20170304306A1 (en) * 2014-09-09 2017-10-26 Chromocell Corporation SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
AU2016268120A1 (en) 2015-05-22 2017-11-30 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
CA3001075C (en) 2015-10-07 2020-10-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Crmp2 sumoylation inhibitors and uses thereof
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
JP6572392B2 (ja) 2015-12-18 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
TW202000651A (zh) 2018-02-26 2020-01-01 美商建南德克公司 治療性組成物及其使用方法
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
MX2021001636A (es) 2018-09-10 2021-05-12 Kaken Pharma Co Ltd Derivado de amida heteroaromatico y medicamento que contiene el mismo.
CA3128809A1 (en) * 2019-02-04 2020-08-13 Simon Fraser University Methods and compounds for inhibition of inactivation of voltage-gated sodium channels
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
SK11542003A3 (sk) * 2001-03-14 2004-07-07 Grnenthal Gmbh Substituované pyrazolopyrimidíny a tiazolopyrimidíny, spôsob ich výroby, liečivá tieto látky obsahujúce a ich použitie
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
RU2006107211A (ru) * 2003-08-08 2007-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005113494A2 (en) 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1802580A2 (en) * 2004-07-23 2007-07-04 Pfizer, Inc. Pyridine derivatives
KR20070068432A (ko) 2004-10-29 2007-06-29 아스트라제네카 아베 염증 질환의 치료를 위한 글루코코르티코이드 수용체조절제로서의 신규 술폰아미드 유도체
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
CA2634743C (en) 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
WO2009012242A2 (en) * 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2009012241A1 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
JP5053459B2 (ja) 2009-01-12 2012-10-17 アイカジェン， インコーポレイテッド スルホンアミド誘導体
CA2761639C (en) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2011133729A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
US9096558B2 (en) * 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
CA2804877A1 (en) * 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
EP2665822A1 (en) 2011-01-18 2013-11-27 Amgen Inc. Nav1.7 knockout mice and uses thereof
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2014078479A2 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
RU2669367C2 (ru) 2013-03-15 2018-10-11 Хромоселл Корпорейшн Модуляторы натриевого канала для лечения боли
CN105530923B (zh) 2013-09-09 2019-07-23 佩洛通治疗公司 芳基醚及其用途
MY181928A (en) 2013-09-10 2021-01-14 Chromocell Corp Sodium channel modulators for the treatment of pain and diabetes

Also Published As

Publication number Publication date
CA2900604A1 (en) 2014-09-25
RU2015133310A3 (es) 2018-02-28
AU2014234105B2 (en) 2019-01-03
CN105188694B (zh) 2018-07-31
HK1219060A1 (zh) 2017-03-24
KR20150131254A (ko) 2015-11-24
RU2015133310A (ru) 2017-04-20
BR112015022096A8 (pt) 2019-11-26
EP2968234A4 (en) 2016-10-12
WO2014151472A1 (en) 2014-09-25
PH12015501740A1 (en) 2015-10-19
ES2687481T3 (es) 2018-10-25
MY188139A (en) 2021-11-23
EP2968234B1 (en) 2018-06-27
EP2968234A1 (en) 2016-01-20
CN105188694A (zh) 2015-12-23
IL242564A0 (en) 2016-02-29
JP6449845B2 (ja) 2019-01-09
BR112015022096A2 (pt) 2017-07-18
MX363680B (es) 2019-03-29
US20160046617A1 (en) 2016-02-18
JP2016512844A (ja) 2016-05-09
US10179781B2 (en) 2019-01-15
RU2669367C2 (ru) 2018-10-11
AU2014234105A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
MX359882B (es) Amidas como moduladores de canales de sodio.
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
NZ750187A (en) Pyridone amides as modulators of sodium channels
PH12015502161A1 (en) Therapeutic compounds and compositions
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
PH12015501609A1 (en) Phenicol antibacterials
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
MX2016001357A (es) Compuestos de ciclobutilo 1,2-disustituidos.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов